CNST

ANALYST NOTE: CNST (Constellation Pharmaceuticals, Inc.) Date: 2026-06-13 Current Price: $33.99

1. Structural Readiness

State: Context-Only (No active technical structure defined in the provided data) Conservative Entry: — Breakout Level: — Extension: — ATR Current: 0.9% (Sub-threshold volatility)

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None named.

Analysis: There is no named secular thesis attached to CNST as of this date. The investment case is strictly tactical, driven by the quality of the technical setup (which is currently absent) and the fundamental progress of the company's clinical pipeline. We must judge this name solely on the execution of its clinical trials and the management's capital allocation, without the tailwinds of a broader macro or sector-specific narrative.

3. Business Fundamentals

Company Profile: Constellation Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to identifying and advancing novel therapeutic solutions. The company's business model relies on the development and commercialization of small-molecule inhibitors targeting epigenetic regulators, specifically in the hematology and solid tumor spaces.

Pipeline Status (As of 2026-06-13):

• Pelabresib (CPI-0610): The lead asset is in the global Phase III pivotal trial (MANIFEST-2). Management has initiated trial sites in both the U.S. and Europe, with dosing underway. The company's goal is to position pelabresib as the backbone of Myelofibrosis (MF) therapy.
• CPI-0209: Progressing through the Phase I dose-escalation segment of a Phase I/II clinical trial for solid tumors.
• Combination Therapy: CPI-0610 is also undergoing Phase II clinical assessment in combination with ruxolitinib for myelofibrosis.

Financial Position (Historical Context): While the most recent financial snapshot in the evidence base is from Q1 2021, it established a cash runway of $382.1 million, sufficient to fund operations into mid-2023. As of 2026, the company is in a post-2023 operational window. The evidence does not provide a current cash balance or burn rate for 2026, creating a significant gap in assessing immediate liquidity risk relative to the current stock price.

4. Archetype and Conviction

Archetype: Growth Leader (Clinical-Stage) Fit: The company fits the "Growth Leader" archetype due to its focus on advancing a lead asset (pelabresib) through Phase III, which represents the highest value inflection point for a biotech firm. The potential to transform the standard of care for myelofibrosis aligns with the margin inflector potential of a successful Phase III readout.

Conviction Stack:

• Thesis Strength: Low. No secular tailwinds; purely tactical.
• Evidence Quality: Mixed. Strong historical evidence of trial initiation (2021), but no current 2026 data on trial completion, enrollment rates, or interim results.
• Structural Quality: Weak. The setup is undefined, and volatility (ATR 0.9%) is sub-threshold, suggesting a lack of institutional positioning or market interest at this specific moment.
• Setup Readiness: None. No breakout or forming coil structure exists.
• Rerating Potential: High *if* Phase III data is positive, but currently unpriced due to the lack of a defined catalyst in the current setup.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Confirmation of successful Phase III enrollment completion and positive interim data for pelabresib.
• Evidence of a new cash infusion or strategic partnership to extend the runway beyond the 2023 baseline.

What Would Invalidate the Case:

• Regulatory delays or failure in the MANIFEST-2 trial.
• Evidence of cash runway exhaustion prior to a commercial milestone.

Gaps in Evidence Base:

• Current Liquidity: No cash balance or burn rate data for 2026. The 2021 data ($382.1M) is obsolete for assessing current solvency.
• Trial Status: No data on the current enrollment status, site activation rates, or projected readout dates for the Phase III trial as of 2026.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: Lead asset pelabresib is in Phase III pivotal trial; company operates as a clinical-stage biopharma with a clear pipeline for myelofibrosis; current price is $33.99. Key risks: No current liquidity data to assess cash runway beyond 2023; technical setup is undefined with sub-threshold volatility; lack of named secular thesis; potential for trial failure or delay. Sizing hint: Position size should be zero or minimal until a technical structure forms and liquidity is confirmed. Expected path: Management will likely provide updates on trial enrollment and data readouts; price will likely remain range-bound or volatile until a binary catalyst event occurs. Expected horizon: Indefinite until Phase III data readout or technical structure formation. Failure mode to watch: A close below a defined support level or evidence of cash runway exhaustion.